Ten kHz spinal cord stimulation for the treatment of chronic peripheral polyneuropathy: 12-Month results from prospective open-label pilot study

被引:7
|
作者
Galan, Vincent [1 ]
Scowcroft, James [2 ]
Chang, Paul [1 ]
Li, Sean [3 ]
Staats, Peter [3 ]
Subbaroyan, Jeyakumar [4 ]
Caraway, David [4 ]
机构
[1] Georgia Pain Care, 1365 Rock Quarry Rd,Suite 202, Stockbridge, GA 30281 USA
[2] KC Pain Ctr, Lees Summit, MO USA
[3] Premier Pain Ctr, Shrewsbury, NJ USA
[4] Nevro Corp, Redwood City, CA USA
关键词
10 kHz SCS; chronic peripheral polyneuropathy; visual analog scale; QUALITY-OF-LIFE; 10-KHZ HIGH-FREQUENCY; CHRONIC PAIN; CHRONIC BACK; NEUROPATHY; OUTCOMES; EFFICACY; LIMB; SCS; MULTICENTER;
D O I
10.1111/papr.13059
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background The goal of this study was to demonstrate that the paresthesia-independent 10 kHz spinal cord stimulation (SCS) can provide long-term pain relief in patients with peripheral polyneuropathy (PPN). Clinically diagnosed subjects with PPN refractory to conventional medical management were enrolled in this prospective, multicenter study between November 2015 and August 2016, after institutional review board approval and patient informed consent were obtained. Methods Subjects underwent trial stimulation utilizing 2 epidural leads, and if successful, were implanted with a permanent 10 kHz SCS system and followed up for 12 months post-implant. Outcome measures included adverse events, pain, neurological assessments, disability, function, quality of life, pain interference, sleep, satisfaction, and global impression of change. Data are presented as descriptive statistics. Permanent implant population results are reported as mean +/- standard error. Results Twenty-one of the 26 trialed subjects had a successful trial and 18 received a permanent implant. All subjects had the leads placed anatomically without the need for paresthesia. Subjects experienced significant and sustained pain relief (at least 65% at all timepoints) whereas physicians noted improvements in neurological function. Significant improvements in disability, function, sleep, sensory, and affective dimensions of pain were reported at all timepoints. All adverse events were resolved without sequelae. Conclusion Findings from this study suggest that 10 kHz SCS may provide sustained pain relief and disability improvements in patients suffering from PPN.
引用
收藏
页码:898 / 906
页数:9
相关论文
共 50 条
  • [21] PERSISTENCE OF SOLIFENACIN TREATMENT IN OVERACTIVE BLADDER PATIENTS IN REAL LIFE PRACTICE: A 12-MONTH, PROSPECTIVE, MULTICENTER, OPEN-LABEL, OBSERVATIONAL STUDY
    Lee, Young-Suk
    Lee, Kyu-Sung
    Jeong, Jeongyun
    Choo, Myung-Soo
    Kim, Joon Chul
    Seo, Ju Tae
    Choi, Jong Bo
    [J]. NEUROUROLOGY AND URODYNAMICS, 2013, 32 (02) : 118 - 119
  • [22] Interferon beta-1a and atorvastatin combination therapy: 12-month results from an open-label, randomized, clinical study
    Orefice, Giuseppe
    Quarantelli, Mario
    Salvatore, Petronilla
    Brunetti, Arturo
    Lanzillo, Roberta
    Prinster, Anna
    Vacca, Giovanni
    Mollica, Carmine
    Bonauita, Vincenzo
    Morra, Vincenzo Brescia
    [J]. NEUROLOGY, 2008, 70 (11) : A85 - A85
  • [23] Safety and Effectiveness of Dasotraline in Binge-Eating Disorder: Results of an Open-Label, 12-Month Extension Study
    Mattingly, Greg
    Tsai, Joyce
    Kent, Justine
    Deng, Ling
    Goldman, Robert
    [J]. NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 113 - 113
  • [24] Comments on "High-frequency spinal cord stimulation (10 kHz) alters sensory function and nerve fiber density in painful diabetic neuropathy: a pilot prospective open-label study"
    Zhou, Peng-Bo
    Li, Wei
    Sun, Hong-Tao
    [J]. PAIN MEDICINE, 2023,
  • [25] Results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia
    Correll, C. U.
    Vanover, K. E.
    Durgam, S.
    Weingart, M.
    Davis, R.
    Satlin, A.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S455 - S456
  • [26] ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat: Results From a 12-Month Open-Label Study
    Beer, Kenneth
    Weinkle, Susan H.
    Cox, Sue Ellen
    Rubin, Mark G.
    Shamban, Ava
    Somogyi, Christine
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (09) : 870 - 877
  • [27] Effectiveness and safety of polyacrylamide hydrogel injection for knee osteoarthritis: results from a 12-month follow up of an open-label study
    Bliddal, Henning
    Beier, Jannie
    Hartkopp, Andreas
    Conaghan, Philip G.
    Henriksen, Marius
    [J]. JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2024, 19 (01):
  • [28] The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study
    Ahn, Yong Min
    Lee, Kyu Young
    Kim, Chul-Eung
    Kang, Dae-Yeob
    Seok, Jeong-Ho
    Shin, Young Min
    Chung, In-Won
    Jun, Tae-Youn
    Chang, Jae Seung
    Kim, Yong Sik
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (08) : 568 - 577
  • [29] FELBAMATE IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME - RESULTS OF A 12-MONTH OPEN-LABEL STUDY FOLLOWING A RANDOMIZED CLINICAL-TRIAL
    DODSON, WE
    [J]. EPILEPSIA, 1993, 34 : S18 - S24
  • [30] A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia
    Perez, Victor
    Canas, Fernando
    Tafalla, Monica
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2008, 23 (03) : 138 - 149